|
 |
| | | | | History | | | | | | | | Biosimilars: Turning visions into reality | | | The use of recombinant biotechnology to manufacture therapeutic drugs is based on a relatively long history. In 1982, recombinant human insulin became the first biotech therapeutic agent to be approved by the US Food and Drug Administration. Other products were launched on the market in the years that followed. Experts predict that the number of newly approved biopharmaceuticals products will soon exceed the number of approved chemical based products.
Joining the biogenerics industry in 2000: BioGeneriX AG
The ratiopharm group recognized this development early on and has been active in the field of biosimilars since the late 1990s. The founding of BioGeneriX in 2000 was the next logical step in the group's business segment strategy.
As a wholly-owned subsidiary of ratiopharm, BioGeneriX focuses on the biopharmaceutical and clinical development of relevant biosimilars as well as me-better proteins.
2004: Founding of Merckle Biotec GmbH
The founding of Merckle Biotec GmbH with investments in biotech multipurpose plants and further investments in the field of pharmaceutical dosage forms represents a complete value-added chain and related expertise within the Merckle/ratiopharm corporate group. This offers key advantages for the development and manufacture of biosimilars with complex structures that require far more intensive efforts than traditional chemical generics.
From clone to market in a one stop shop strategy. A business area segment strategy becomes reality.
| | | | | | | | |
|
|
|
Links